June 03, 2026 a 07:43 pm
VRTX: Fundamental Ratio Analysis - Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals has shown robust growth, driven by its leading position in the cystic fibrosis treatment market. The company's strong pipeline and strategic collaborations position it well for future developments. Investors should consider both the potential and the inherent risks associated with the biotech industry.
Fundamental Rating
Vertex Pharmaceuticals receives a rating of A-, indicating strong fundamentals with room for improvement. Below are key financial metrics with associated scores
| Category | Score | |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 3 | |
| Price to Earnings | 2 | |
| Price to Book | 1 |
Historical Rating
The historical data illustrates Vertex Pharmaceuticals' consistent performance with a stable outlook.
| Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-06-03 | 4 | 4 | 5 | 5 | 3 | 2 | 1 |
| Before | 0 | 4 | 5 | 5 | 3 | 2 | 1 |
Analyst Price Targets
Analysts set a high price target of $616, showcasing optimism in Vertex's future market position.
| High | Low | Median | Consensus |
|---|---|---|---|
| $616 | $436 | $558 | $553.93 |
Analyst Sentiment
Overall sentiment among analysts is positive with a consensus rating of 'Buy'.
| Rating | Count | |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 48 | |
| Hold | 8 | |
| Sell | 0 | |
| Strong Sell | 0 |
Conclusion
Vertex Pharmaceuticals is a leader in its market segment due to its innovative cystic fibrosis treatments and robust pipeline. However, reliance on the biotech sector's inherent volatility and the success of future clinical trials could influence its valuation. The stock's "Buy" rating and high price targets suggest confidence in its growth prospects. Potential investors should weigh the company's strong industry position against the risks posed by regulatory and market changes. The overall ratings and trends indicate a positive trajectory but require diligent monitoring.
Smart Data Insight
Master the Perfect Entry & Exit for this Stock
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.
- ✅ Identify the "Golden Buying Window"
- ✅ Avoid high-risk correction cycles
- ✅ Backtested data from the last 20+ years